An oral IL-23 receptor blocker clears psoriasis and holds the response at a year

Design

Two phase 3, placebo- and active-comparator (deucravacitinib) controlled randomised trials, 52 weeks

Population

1505 adults with moderate-to-severe plaque psoriasis

Primary outcome

Skin clearance (IGA 0/1, PASI 90) and complete clearance (IGA 0, PASI 100)

Effect

About 70-75% IGA 0/1 and PASI 90, roughly 50% PASI 100 during weeks 24-52; response durable to week 52

Most highly effective psoriasis drugs are injectable biologics. Icotrokinra is a once-daily oral peptide that blocks the interleukin-23 receptor, and this report gives one-year outcomes from two phase 3 trials, ICONIC-ADVANCE 1 and 2, in 1505 adults with moderate-to-severe plaque psoriasis, against both placebo and the oral agent deucravacitinib.

Skin clearance rose through week 24 and held to week 52: roughly 70 to 75% of those on icotrokinra had clear or almost clear skin, and about half reached complete clearance during weeks 24 to 52. Of those clear or almost clear at week 16, around 85 to 90% maintained it at a year. Patients switched from placebo or deucravacitinib caught up to similar response rates. Adverse events matched placebo through week 16 and were fewer than with deucravacitinib through week 24, with no new safety signals.

An oral drug that approaches biologic-level clearance would matter for patients who refuse or cannot use injections. Where it is available, it becomes a real oral option for moderate-to-severe disease; its place against established IL-23 biologics will depend on longer comparison and on cost.

• Icotrokinra is a once-daily oral peptide blocking the interleukin-23 receptor, studied in 1505 adults over 52 weeks.
• About 70 to 75% reached clear or almost clear skin and roughly half complete clearance during weeks 24 to 52.
• Around 85 to 90% of those clear or almost clear at week 16 maintained response at one year.
• Adverse events matched placebo early and were fewer than with deucravacitinib through week 24.
• Consider it an oral option for patients who decline or cannot use injectable biologics, where access allows.

Why it matters

It raises the ceiling for oral psoriasis therapy towards what injectable biologics achieve, which changes the conversation for injection-averse patients.

Don't overread it

The active-comparator advantage was demonstrated versus deucravacitinib through week 24, not against injectable IL-23 biologics, so it does not establish superiority over current first-line biologics.

The statistics, in plain English

These are response rates rather than a single effect size; the comparison with deucravacitinib favoured icotrokinra on clearance and early safety, but head-to-head data against injectable IL-23 biologics are not provided here.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.